The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Fasting After Single Ascending Oral Doses of AZD5658 in Type 2 Diabetes Mellitus Patients
- collapse A randomized, single-blind, placebo-controlled, phase I study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD1656 compared to placebo in T2DM patients treated with metformin and sulfonylurea
- collapse A Randomised, Single-Blind, Placebo-Controlled, Phase IIA Study to Assess the Safety and Tolerability after Multiple Oral Doses of AZD1656 in Patients with Type 2 Diabetes Mellitus Treated with Metformin
- collapse A Randomised, Two Way Cross-over, Single-Blind, Phase I Study to Evaluate 24-hr Glucose Profiles in Patients with T2DM when Dosed OD and BD on Top of Metformin for Four Days with AZD1656
- collapse A Randomized, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics after Multiple Ascending Oral Doses of AZD1656 in subjects with T2DM treated with Metformin
- collapse A Randomized, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics after Multiple Ascending Oral Doses of AZD1656 in subjects with T2DM treated with Insulin
- collapse A Randomized, Open, Two-Way Cross-Over, Single-Centre, Phase I Study to Assess the Counter regulatory Response during Hypoglycaemia in Healthy Male Volunteers after a Single Oral Dose of AZD1656 Suspension in Comparison with Insulin Infusion
- collapse A Randomized, Open, Single-Dose, Single-Centre, cross-over, Phase I Study in type 1 diabetes mellitus patients to estimate the extent and rate of absorption of AZD1656 after administration of a tablet formulation in the fasting state and just before food in comparison with an oral suspension of AZD1656
- collapse An open, single-centre, single group, Phase I study to assess the absorption, distribution, metabolism and excretion (ADME) of AZD1656 after oral administration of 14C-labelled AZD1656 to Type II Diabetes Mellitus patients
- collapse A Randomized, Single-blind, Placebo-Controlled, Multi-centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics after Multiple Ascending Oral Doses of AZD1656 in Japanese T2DM Patients
